Atorvastatin Does Not Affect the Antiplatelet Potency of Clopidogrel When It Is Administered Concomitantly for 5 Weeks in Patients With Acute Coronary Syndromes

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Circulation

• Publication date

  2004-03-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000124581.18191.15PMID 15023882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mapping the binding domains of the αIIb subunit

  2003cited by this paper
• Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial

  2003cited by this paper
• Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.

  2003cited by this paper
• Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction

  2003cited by this paper
• Soluble CD40 ligand in acute coronary syndromes.

  2003cited by this paper
• Mapping the binding domains of the alpha(IIb) subunit. A study performed on the activated form of the platelet integrin alpha(IIb)beta(3).

  2003cited by this paper
• Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel

  2003cited by this paper
• Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB

  2002cited by this paper
• Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type Gi‐linked P2T antagonist, CS‐747

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets

  2001cited by this paper
• Identification and Biological Activity of the Active Metabolite of Clopidogrel

  2000cited by this paper
• Differential metabolism of statins: importance in drug-drug interactions

  1999cited by this paper
• In vitro and in vivo drug interactions involving human CYP3A.

  1998cited by this paper
• Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

  1998cited by this paper
• Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease.

  1995cited by this paper

• Effect of LDL-Cholesterol Levels and Oral Atorvastatin on Outcomes After Pipeline Therapy for Intracranial Aneurysms

  2025cites this paper
• Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro

  2024cites this paper
• Current and Future Roles of Glycoprotein IIb–IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction

  2024cites this paper
• Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy.

  2023cites this paper
• Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients

  2022cites this paper
• Antiplatelet Therapy

  2020cites this paper
• Circulating progenitor cells and their interaction with platelets in patients with an acute coronary syndrome

  2019cites this paper
• Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis

  2019cites this paper
• Drug-Drug Interactions in Acute Coronary Syndrome Patients: Systematic Review

  2019cites this paper
• Laboratory Monitoring of Antiplatelet Therapy

  2019cites this paper
• Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?

  2018cites this paper
• The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry

  2017cites this paper
• Assessment of clopidogrel discontinuation rates following pharmacogenomic testing in a high-risk patient population : an interim analysis of the UPGRADE Registry

  2017cites this paper
• Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy

  2016cites this paper
• Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future

  2015cites this paper
• Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention.

  2015cites this paper
• Proton pump inhibitors and clopidogrel: an association to avoid?

  2014cites this paper
• Antiplatelet response to aspirin and clopidogrel in patients with coronary artery disease undergoing percutaneous coronary intervention

  2014cites this paper
• ASSESSMENT OF ADVERSE EFFECT OF ATORVASTATIN WITH PLATELET P2Y 12 -ADP RECEPTOR ANTAGONIST ON PLATELETS AGGREGATION AND RENAL FUNCTION IN CORONARY HEART DISEASE TREATED PATIENTS

  2014cites this paper
• Risk Factor Analysis for Incidence of Major Adverse Cardiac Events after Percutaneous Coronary Intervention Treatment

  2014cites this paper
• ADP Receptor Antagonists

  2013cites this paper
• Combined antiplatelet therapy: still a sweeping combination in cardiology.

  2013cites this paper
• High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.

  2013cites this paper
• Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?

  2013cites this paper
• Drug interactions with statins

  2013cites this paper
• Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part II: Potential causes and laboratory tests.

  2013cites this paper
• Do MDR1 and SLCO1B1 Polymorphisms Influence the Therapeutic Response to Atorvastatin? A Study on a Cohort of Egyptian Patients with Hypercholesterolemia

  2013cites this paper
• Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences.

  2013cites this paper
• Interacciones medicamentosas de agentes hipolipemiantes: aproximación para establecer y valorar su relevancia clínica. Revisión estructurada

  2013cites this paper
• ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.

  2013cites this paper
• Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms

  2013cites this paper
• Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.

  2013cites this paper
• Einfluss genetischer Polymorphismen auf das Ansprechen der antithrombotischen Therapie und die klinische Prognose bei kardiovaskulären Risikofaktoren

  2013cites this paper
• Genetic and non-genetic factors affecting the response to clopidogrel therapy

  2012cites this paper
• Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives

  2012cites this paper
• Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.

  2012cites this paper
• Drugs that Affect Platelet Function

  2012cites this paper
• Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate

  2012influential citation
• Drug-drug interactions in cardiovascular catheterizations and interventions.

  2012cites this paper
• Platelet-mediated inflammation in cardiovascular disease. Potential role of platelet-endothelium interactions.

  2012cites this paper
• The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment

  2012cites this paper
• Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome

  2012cites this paper
• Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.

  2012cites this paper
• [Pharmacogenetics of clopidogrel and its clinical significance].

  2012cites this paper
• Clopidogrel

  2012cites this paper
• Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.

  2011cites this paper
• Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.

  2011cites this paper
• Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy

  2011cites this paper
• The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.

  2011cites this paper
• Managing adverse effects and drug–drug interactions of antiplatelet agents

  2011cites this paper
• Platelet function variability and non-genetic causes

  2011cites this paper
• Clopidogrel differentially affects platelet‐mediated thrombosis and inflammatory response in patients with acute coronary syndromes

  2011cites this paper
• Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel

  2011cites this paper
• Effect of Atorvastatin and Clopidogrel Co-Administration After Coronary Stenting in Korean Patients With Stable Angina

  2011cites this paper
• Influence of high‐density lipoprotein and paraoxonase‐1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy

  2011cites this paper
• Antiplatelet resistance in stroke

  2011cites this paper
• Clopidogrel resistance: current aspects and future directions.

  2011cites this paper
• Statins have an early antiplatelet effect in patients with acute myocardial infarction

  2011cites this paper
• Review: Antiplatelet Therapy in Acute Coronary Syndromes

  2011cites this paper
• Clopidogrel-drug interactions.

  2011cites this paper
• Mechanisms of platelet activation and modification of response to antiplatelet agents.

  2011cites this paper
• A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents

  2010cites this paper
• Clopidogrel resistance.

  2010cites this paper
• Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro

  2010cites this paper
• Clopidogrel Provides Significantly Greater Inhibition of Platelet Activity Than Aspirin When Combined With Atorvastatin After Coronary Artery Bypass Grafting: A Prospective Randomized Study

  2010cites this paper
• With Atorvastatin After Coronary Artery Bypass Grafting : A Prospective Randomized Study Clopidogrel Provides Significantly Greater Inhibition of Platelet Activity Than Aspirin When Combined

  2010cites this paper
• Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.

  2010cites this paper
• Epidemiology of Cytochrome P450-mediated Drug-Drug Interactions

  2010cites this paper
• Clinical importance of aspirin and clopidogrel resistance.

  2010cites this paper
• Die hemmende Wirkung von Clopidogrel auf die Aggregation humaner Thrombozyten

  2010cites this paper
• Advance of pharmacological studies on clopidogrel, a prodrug with high-risk pharmacokinetics

  2010cites this paper
• Die hemmende Wirkung von Clopidogrel auf die Aggregation humaner Thrombozyten

  2010cites this paper
• Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome

  2010cites this paper
• Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization.

  2010cites this paper
• From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand.

  2010cites this paper
• The antiplatelet and antithrombotic actions of statins.

  2010cites this paper
• The potential interaction between clopidogrel and proton pump inhibitors: a systematic review

  2010cites this paper
• Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation).

  2010cites this paper
• Atorvastatin: safety and tolerability

  2010cites this paper
• Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond

  2009cites this paper
• Influence of statin treatment on platelet inhibition by clopidogrel – a randomized comparison of rosuvastatin, atorvastatin and simvastatin co‐treatment

  2009cites this paper
• [Clopidogrel resistance].

  2009cites this paper
• Prasugrel: A Critical Comparison with Clopidogrel

  2009cites this paper
• Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.

  2009cites this paper
• Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies.

  2009cites this paper
• Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients

  2009cites this paper
• Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers

  2009cites this paper
• Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes

  2009cites this paper
• Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention.

  2009cites this paper
• Antiplatelet Activity of Clopidogrel was not Reduced by Long-termCoadministration of Atorvastatin Compared with Coadministration ofFluvastatin

  2009cites this paper
• Überprüfung der Wirksamkeit einer antithrombozytären Therapie mit Acetylsalicylsäure und Clopidogrel bei Patienten nach koronarer Stentimplantation unter Verwendung der Impedanz Aggregometrie

  2009cites this paper
• Individualised Antiplatelet Therapy - Is There a Role for Platelet Function Testing in Routine Clinical Practice?

  2009cites this paper
• Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome.

  2009cites this paper
• Personalized medicine and antiplatelet therapy: ready for prime time?

  2009cites this paper
• PLATELETS IN HEMATOLOGIC AND CARDIOVASCULAR DISORDERS: A CLINICAL HANDBOOK

  2008cites this paper
• Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

  2008cites this paper
• Aspirin and clopidogrel response variability: review of the published literature.

  2008cites this paper
• Acute and long-term antiplatelet therapy.

  2008cites this paper
• High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.

  2008cites this paper
• Einfluss von Statinen auf die antithrombozytäre Wirkung von Clopidogrel nach Stentimplantation

  2008cites this paper